Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer. PET using ER- and PR-specific radioligands enables a whole-body, noninvasive assessment of receptor expression. Recent investigations of ER imaging with ¹⁸F-fluoroestradiol have focused on diagnosing ER-positive metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit. Studies of PR imaging with ¹⁸F-fluorofuranyl norprogesterone have investigated how imaging changes in PR expression as a downstream target of ER activation may reflect an early response to ER-targeted therapy. This focused review highlights recent achievements in preclinical and clinical imaging of ER and PR in breast cancer.

雌激素受体（ER）和孕激素受体（PR）是乳腺癌的重要预后和预测生物标志物。使用ER和PR特异性放射性配体的PET可以对受体表达进行全身性，非侵入性评估。用¹⁸ F-氟雌二醇进行ER成像的最新研究集中于诊断ER阳性转移性疾病，优化ER靶向药物的剂量以及预测内分泌治疗的益处。用¹⁸ F-氟呋喃基去甲孕酮进行PR成像的研究已经研究了PR表达的成像变化如何作为ER激活的下游靶点可能反映对ER靶向治疗的早期反应。这篇重点综述着重介绍了乳腺癌中ER和PR的临床前和临床成像方面的最新成就。